Best Platforms for Sharing Clinical Trial Data Responsibly and Transparently

Introduction: Why Repository Selection Matters

As open data becomes a regulatory and ethical expectation in clinical research, selecting the right data repository is critical. A good repository ensures data security, metadata integrity, ease of access for researchers, and compliance with global transparency mandates. With numerous platforms available, sponsors and researchers must understand which repositories align with their data type, jurisdiction, and privacy standards.

This tutorial reviews the top global repositories used to share clinical trial data, highlighting features, regulatory alignment, and use cases. The right choice not only fulfills obligations but enhances the visibility, utility, and impact of trial results.

Types of Clinical Trial Repositories

Clinical trial data can be deposited in several types of repositories:

• Regulatory Registries: Required by authorities (e.g., ClinicalTrials.gov, EU CTR)
• Open Data Platforms: Allow public access (e.g., Dryad, Figshare)
• Controlled-Access Repositories: Require request and approval (e.g., Vivli, YODA)
• Sponsor-Owned Portals: Managed by pharmaceutical companies or CROs

Each category serves different access levels and privacy safeguards, and often a combination is used for broad compliance and discoverability.

Repository Comparison Table

1. ClinicalTrials.gov – The Primary US Registry

Operated by the U.S. National Library of Medicine, ClinicalTrials.gov is a mandatory repository for most interventional studies conducted under FDA jurisdiction. It includes trial registration, summary results, and outcome measures.

Key Features:

• Accepts summary results in tabular format
• Structured data entry via PRS (Protocol Registration System)
• Used to assess compliance under FDAAA 801
• Global visibility and indexing

Explore ClinicalTrials.gov

2. Vivli – A Global Controlled-Access Platform

Vivli.org is a nonprofit data sharing platform that hosts individual participant-level data (IPD) and supports cross-sponsor collaboration. It enables researchers to access de-identified datasets following a formal proposal and approval process.

Highlights:

• Secure cloud-based environment for data access
• Used by industry sponsors, academia, and funders
• Supports metadata linkage with DOIs and publications
• Supports compliance with EMA Policy 0070 and ICMJE

Vivli promotes transparency while protecting participant confidentiality through strict governance models.

3. YODA Project – Yale Open Data Access

The YODA Project facilitates access to participant-level clinical trial data, originally launched with Johnson & Johnson trials. Like Vivli, it provides controlled access but with academic stewardship from Yale University.

Benefits:

• Transparent and independent data review committee
• Peer-reviewed request process
• Wide range of therapeutic areas and sponsors
• Ideal for systematic reviews and re-analyses

YODA ensures ethical, scientific, and secure reuse of trial datasets for non-commercial academic purposes.

4. Dryad – An Open Access Research Repository

Dryad is a general-purpose data repository used by many medical and biological journals to host underlying datasets. It supports FAIR (Findable, Accessible, Interoperable, Reusable) principles.

Attributes:

• Open access with DOI assignment
• Simple CSV/Excel upload format
• Supports data citation in journal publications
• Useful for protocol-linked data tables

While not trial-specific, Dryad offers wide reach for published datasets supporting transparency and reproducibility.

5. EU Clinical Trials Register (EUCTR)

Managed by the EMA, the EUCTR provides public access to clinical trials conducted in the EU. It includes trial design, sponsor info, and results summaries, aligned with the EU Clinical Trials Regulation (CTR).

Core Capabilities:

• Automatically populated via national competent authorities
• Open access portal
• Supports results posting and EudraCT ID linkage
• Essential for compliance with EU CTR

While limited in accepting raw datasets, EUCTR plays a critical role in regulatory and public transparency.

Honorable Mentions and Niche Repositories

• ISRCTN Registry – Offers DOI assignment and metadata enhancement
• Zenodo – EU-backed repository for all disciplines, including clinical data
• Figshare – Supports supplemental materials and interactive visualizations
• OpenTrials.net – Curates trial information from multiple sources

Some funders and journals also maintain their own repositories — always check sponsor-specific data sharing policies.

Choosing the Right Repository: Decision Factors

When selecting a repository, consider the following:

• Regulatory obligations – Some registries are legally required (e.g., ClinicalTrials.gov)
• Data type – IPD vs summary data
• Access model – Open vs controlled
• Anonymization requirements – Privacy law compliance
• Discoverability – DOI assignment, indexing, and citation metrics

Multi-platform upload is also common: registration in one platform, datasets in another, and publications linked to both.

Conclusion: Enabling Transparency Through Strategic Repository Use

Repositories are vital infrastructure for global clinical trial transparency. They empower open science, reinforce participant trust, and accelerate therapeutic innovation. By understanding each platform’s strengths, access policies, and submission standards, trial sponsors and investigators can choose the most effective way to disseminate data and meet compliance expectations. Transparency is no longer optional — and these repositories are the gateways to achieving it.

Comparing FDAAA and EU CTR: A Deep Dive into Trial Disclosure Regulations

Introduction: Why Understanding These Differences Matters

With increasing globalization of clinical research, sponsors often conduct trials in both the United States and the European Union. Understanding the distinctions between the U.S. FDAAA 801 Final Rule and the EU Clinical Trials Regulation (CTR) is critical to ensuring full compliance and avoiding penalties.

Though both frameworks share a common objective—to ensure timely and public access to clinical trial data—they differ significantly in structure, implementation, reporting timelines, and enforcement. Misalignment can lead to regulatory breaches, funding rejections, or ethical concerns. This article outlines the key contrasts and offers a side-by-side view of what sponsors must know.

Disclosure Scope: What Trials Are Covered?

FDAAA 801 applies to “Applicable Clinical Trials” (ACTs), including controlled clinical investigations (other than Phase I) of FDA-regulated drugs, biological products, and devices. Exemptions include Phase I trials and small feasibility studies for devices.

EU CTR, on the other hand, applies to all interventional trials on medicinal products intended for human use conducted in at least one EU/EEA Member State. This includes Phase I trials, pediatric studies, and bioequivalence trials, which are often excluded from FDAAA’s disclosure scope.

Registration Requirements and Timelines

Under FDAAA, trial registration must occur no later than 21 days after the enrollment of the first participant. Registration includes details such as sponsor name, conditions studied, eligibility criteria, outcomes, and locations.

With the EU CTR, registration must happen prior to the trial start, meaning before the first subject is enrolled. This mandatory prospective registration ensures full transparency from the outset.

Moreover, the EU CTR uses a single-entry system—CTIS—making it easier to track compliance. In contrast, ClinicalTrials.gov allows sponsors to manage studies independently with fewer centralized controls.

Result Disclosure Timelines and Content

One of the most notable differences lies in result submission:

• FDAAA 801: Results must be posted within 12 months of the primary completion date.
• EU CTR: Results must be posted within 12 months of the end of the trial. Pediatric studies require reporting within 6 months.

Additionally, the EU CTR mandates Lay Summaries written in plain language and public availability of the protocol and assessment reports post-study. FDAAA does not require lay summaries, although structured result tables and adverse event data are mandatory.

Data Elements and Registry Structure

Both registries require similar core data—such as trial phase, interventions, and endpoints—but differ in their formats and user interfaces:

Public Access to Information and Redactions

CTIS enables automatic publication of key documents, including protocol synopsis, investigator brochures, and assessment reports. It uses a deferral system to delay publication of sensitive commercial data, but full disclosure is the default.

ClinicalTrials.gov provides structured tabular result data and allows public access but does not release full protocols or supporting documents unless added manually. The redaction process is sponsor-controlled.

Adverse Event Reporting

Under FDAAA, sponsors must submit structured Serious and Non-Serious Adverse Events in tabular format. These include frequency thresholds (e.g., ≥5%) and system-organ classification. Events are categorized by arm and severity.

In contrast, the EU CTR integrates adverse event summaries into the broader study report structure. While less tabular, it includes narrative-level data and often overlaps with EudraVigilance safety reporting.

Legal Penalties and Enforcement Mechanisms

FDAAA violations are subject to civil monetary penalties. In 2025, the fine stands at $13,237 per day of noncompliance. The FDA publicly lists sponsors who fail to report required data. NIH-funded researchers may lose grant eligibility.

The EU CTR enforces penalties at the Member State level. These may include trial suspension, ethics committee action, or rejection of future applications. EMA audits the CTIS system for systemic noncompliance and supports corrective actions.

Multinational Trial Considerations

When conducting global trials, sponsors must comply with both FDAAA and EU CTR concurrently. This means dual registry management—using both ClinicalTrials.gov and CTIS—and aligning timelines. The use of Clinical Trial Management Systems (CTMS) integrated with registry APIs is recommended to synchronize submissions.

For example, a U.S.-based sponsor enrolling in Germany must register in CTIS before the trial starts there, while still registering on ClinicalTrials.gov within 21 days of enrolling the first U.S. participant.

Case Study: Reporting a Pediatric Oncology Trial

A Phase II pediatric oncology trial conducted in both the U.S. and France offers insight:

• In the U.S., the sponsor reported results 12 months after primary completion using ClinicalTrials.gov. Lay summaries and protocols were not disclosed.
• In France, the same trial was submitted to CTIS and required both technical and lay summaries, protocol disclosure, and public posting of the assessment report within 6 months of completion.

This example highlights the additional transparency obligations under the EU CTR, especially for pediatric studies.

Summary: Aligning Global Disclosure Strategies

While FDAAA and EU CTR share common goals of trial transparency, their implementation differs. Sponsors must:

• Track and comply with jurisdiction-specific timelines
• Ensure dual registration for multinational trials
• Prepare lay summaries for EU trials
• Use structured templates and automated systems for compliance

Failure to do so can result in reputational damage, financial penalties, and even legal action. Harmonizing regulatory strategy is no longer optional—it is a core function of ethical and operational trial conduct.